Protecting against opioid-induced adverse events Prophylaxis for constipation—the most common opioid-induced adverse event—has been facilitated by the approval of methylnaltrexone subcutaneous administration and naloxegol oral administration for
patients with chronic non-cancer pain. Other, less expensive medications like senna and docusate, are also effective to guard against constipation. Table 6: Recommendations for preventing or treating opioid-induced side effects 140
Table 6: Recommendations for preventing or treating opioid-induced side effects 140
Constipation
Methylnaltrexone or naloxegol Prophylactic mild peristaltic stimulant (e.g. bisacodyl or senna) If no bowel movement for 48 hours, increase dose of bowel stimulant If no bowel movement for 72 hours, perform rectal exam If not impacted, provide additional therapy (suppository, enema, magnesium citrate, etc.)
Nausea or vomiting
Consider prophylactic antiemetic therapy Add or increase non-opioid pain control agents (e.g. acetaminophen) If analgesia is satisfactory, decrease dose by 25% Treat based on cause
Sedation
Determine whether sedation is due to the opioid – if so, lower opioid dose immediately Eliminate nonessential CNS depressants (such as benzodiazepines) Reduce dose by 20-30% Add or increase non-opioid or non-sedating adjuvant for additional pain relief (such as NSAID or acetaminophen)so the opioid can be reduced Change opioid Prescribe naloxone
Pruritus
Consider treatment with antihistamines Change opioid
Hallucination or dysphoria
Evaluate underlying cause Eliminate nonessential CNS acting medications
Sexual dysfunction Reduce dose
Testosterone replacement therapy may be helpful (for men) Erection-enhancing medications (e.g., sildenafil)
Both male and female patients on long-term opioid therapy are at risk for hypogonadism, thus current guidelines suggest that the endocrine function of all Naloxone for opioid overdose Naloxone (e.g., Narcan) is an opioid antagonist that quickly reverses the effects of opioid overdose. Naloxone is increasingly available to first responders, patients, and friends and family members of those prescribed opioids, and a generic formulation of nasal-spray naloxone was approved by the FDA in April, 2019. 141 Primary care providers should prescribe naloxone to patients at risk of overdose, including those: ● With renal or hepatic dysfunction ● Taking opioid doses >50 MMED ● Co-prescribed benzodiazepines or other sedating medications ● With a history of overdose or OUD ● Starting treatment for opioid use disorder Successful opioid tapering Patients who do not achieve functional goals on stable or increasing opioid doses or those with unacceptable side effects, should have the opioid
patients should be assessed at the start of long-term opioid therapy and at least annually thereafter.
Many states allow patients, family members, caregivers, and/or friends to request naloxone from their local pharmacist. Anyone receiving naloxone should be taught how to use the device and about the common signs of overdose (slow or shallow breathing, gasping for air, unusual snoring, pale or bluish skin, not waking up or responding, pin point pupils, slow heart rate). A variety of naloxone products are available. The intranasal device with atomizer and intramuscular (IM) shots require the most manipulation in order to administer. Intranasal naloxone and the auto-IM injector are easier to use, but vary greatly in terms of price and insurance coverage.
tapered or discontinued. Patients sometimes resist tapering or discontinuation, fearing increased pain. However, a 2017 systematic review found that dose
Page 24
Book Code: MDAZ1124
Powered by FlippingBook